Literature DB >> 34543650

Combined and sequential effects of alcohol and methamphetamine in animal models.

Alexandra M Stafford1, Bryan K Yamamoto2, Tamara J Phillips3.   

Abstract

Comorbid drug use, often alcohol with other drugs, poses significant health and societal concerns. Methamphetamine is among the illicit drugs most often co-used with alcohol. The current review examines the animal literature for impacts of comorbid alcohol and methamphetamine exposure. We found evidence for additive or synergistic effects of combined or sequential exposure on behavior and physiology. Dopaminergic, serotonergic, and glutamatergic systems are all impacted by combined exposure to alcohol and methamphetamine and cyclooxygenase-2 activity plays an important role in their combined neurotoxic effects. Adverse consequences of comorbid exposure include altered brain development with prenatal exposure, impaired learning and memory, motor deficits, gastrotoxicity, hepatotoxicity, and augmented intake under some conditions. Given high susceptibility to drug experimentation in adolescence, studies of co-exposure during the adolescent period and of how adolescent exposure to one drug impacts later use or sensitivity to the other drug should be a priority. Further, to gain traction on prevention and treatment, additional research to identify motivational and neurobiological drivers and consequences of comorbid use is needed.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Alcohol use disorder; Amphetamine; Comorbid drug use; Ethanol; Neurotoxicity; Substance use disorder

Mesh:

Substances:

Year:  2021        PMID: 34543650      PMCID: PMC8642292          DOI: 10.1016/j.neubiorev.2021.09.019

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  211 in total

Review 1.  Sex Differences in Animal Models: Focus on Addiction.

Authors:  Jill B Becker; George F Koob
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

2.  Chronic ethanol exposure leads to divergent control of dopaminergic synapses in distinct target regions.

Authors:  Julie C Healey; Danny G Winder; Thomas L Kash
Journal:  Alcohol       Date:  2008-03-20       Impact factor: 2.405

3.  Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity.

Authors:  David M Thomas; Donald M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  2005-02-17       Impact factor: 4.030

4.  Enhancement of amphetamine- and cocaine-induced locomotor activity after chronic ethanol administration.

Authors:  S J Manley; H J Little
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

5.  The effects of chronic amphetamine treatment on prenatal ethanol-induced changes in dopamine receptor function: electrophysiological findings.

Authors:  R Y Shen; J H Hannigan; L A Chiodo
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

6.  Methamphetamine-Induced Brain Injury and Alcohol Drinking.

Authors:  Amanda L Blaker; Bryan K Yamamoto
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-30       Impact factor: 4.147

7.  Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood-brain barrier.

Authors:  Nicole A Northrop; Bryan K Yamamoto
Journal:  J Neuroimmune Pharmacol       Date:  2012-07-26       Impact factor: 4.147

8.  Mice selectively bred for high- or low-alcohol-induced locomotion exhibit differences in dopamine neuron function.

Authors:  Michael J Beckstead; Tamara J Phillips
Journal:  J Pharmacol Exp Ther       Date:  2009-01-02       Impact factor: 4.030

9.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.

Authors:  J P O'Callaghan; D B Miller
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

10.  The role of alcohol response phenotypes in the risk for alcohol use disorder.

Authors:  Andrea C King; Dingcai Cao; Harriet deWit; Sean J O'Connor; Deborah S Hasin
Journal:  BJPsych Open       Date:  2019-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.